Background-The relationship between white blood cell count (WBCc) and mortality in patients with ST-segmentelevation acute myocardial infarction treated with percutaneous coronary intervention is poorly understood. Furthermore, whether there is a relationship between WBCc and risk of noncardiac mortality and bleeding after percutaneous coronary intervention is unknown. Methods and Results-The baseline WBCc was available in 3193 of 3345 patients (95.5%) who underwent percutaneous coronary intervention in the Harmonizing Outcome With Revascularization and Stent in Acute Myocardial Infarction (HORIZONS-AMI) trial. In a propensity-adjusted multivariable analysis, WBCc was an independent predictor of 1-year cardiac mortality (hazard ratio, 1.15; 95% confidence interval, 1.09 to 1.22), noncardiac mortality (hazard ratio, 1.19; 95% confidence interval, 1.10 to 1.29), and major bleeding (hazard ratio, 1.08; 95% confidence interval, 1.04 to 1.12). After adjustment for baseline creatinine phosphokinase levels and left ventricular ejection fraction, WBCc remained an independent predictor of 1-year all-cause mortality and cardiac mortality. In patients matched for baseline creatinine phosphokinase levels at hospital admission, the median peak creatinine phosphokinase level was significantly higher in patients with high WBCc (Ͼ11 000 per 1 mm 3 ) compared with low WBCc (1851 U/L [range, 880-3307 U/L] versus 1241 U/L [range, 540 to 2,78], respectively; PϽ0.0001). In this subgroup of patients, WBCc was an independent correlate of peak creatinine phosphokinase level, and remained an independent predictor of 1-year mortality. Conclusions-In patients with ST-segment-elevation acute myocardial infarction undergoing percutaneous coronary intervention, elevated baseline WBCc is an independent predictor of infarct size, as assessed by peak creatinine phosphokinase level, and of 1-year cardiac mortality, noncardiac mortality, and major bleeding. Clinical Trial Registration-URL: http://www.ClinicalTrials.gov. Unique identifier: NCT00433966.
A n association between the admission white blood cell count (WBCc) and morbidity and mortality in patients with ST-segment-elevation acute myocardial infarction (STEMI) has been reported for more than half a century. 1 Although this association has also been described for patients with STEMI undergoing lytic therapy, 2, 3 WBCc studies in STEMI patients undergoing primary percutaneous coronary intervention (PCI) have reported conflicting findings. Some studies have found WBCc to be an independent predictor of 1-year mortality after primary PCI, 4, 5 whereas others have refuted this association. 6, 7 Moreover, no previous study has investigated the relation between WBCc and bleeding or infarct size in patients undergoing primary PCI. We therefore sought to investigate the impact of WBCc on 1-year all-cause mortality, cardiac mortality, noncardiac mortality, bleeding, and infarct size in patients enrolled in the large-scale, pro-spective, randomized Harmonizing Outcome With Revascularization and Stent in Acute Myocardial Infarction (HORIZONS-AMI) trial. 8 
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Methods
The study design of the HORIZONS-AMI trial has previously been reported in detail. 9 Briefly, HORIZONS-AMI was a prospective randomized trial including consecutive patients Ն18 years of age who presented within 12 hours after the onset of symptoms with ST-segment elevation of Ն1 mm in Ն2 contiguous leads, new left bundle-branch block, or true posterior infarction. Patients were randomized before angiography in a 1:1 ratio to anticoagulation with unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor or to the direct thrombin inhibitor bivalirudin alone. After angiography, stenteligible patients were randomized in a 3:1 ratio to paclitaxel-eluting or bare metal stents. All adverse cardiac and bleeding events were adjudicated by an independent clinical events committee blinded to treatment assignment. The study was approved by the institutional review board or ethics committee at each participating center, and all patients provided written informed consent. Blood samples were obtained at the time of admission at each participating center and recorded in the electronic case report form. Total WBCc was measured in an EDTA-anticoagulated whole-blood specimen.
Study Objectives and Definitions
For the purpose of this study, we included only patients treated with primary PCI who had a baseline WBCc obtained. The primary objective of this study was to evaluate the impact of WBCc on 1-year mortality. Secondary objectives of the study were to evaluate the impact of WBCc on reinfarction, target vessel revascularization, stent thrombosis defined according to the Academic Research Consortium definition, 10 and major bleeding not related to coronary artery bypass surgery. We also sought to determine the relationship of WBCc to infarct size as assessed by peak creatinine phosphokinase (CPK) levels. The primary end-point definitions in the HORIZON trial have previously been reported in detail. 9 In addition, cardiac mortality was adjudicated as death caused by any of the following: acute MI, cardiac perforation or pericardial tamponade, arrhythmia or conduction abnormality, stroke, or procedural complication. Any death in which a cardiac cause could not be excluded was also adjudicated as cardiac.
Statistical Analysis
Categorical variables were compared by the 2 or Fisher exact test. Continuous data are presented as meanϮSD or median and interquartile range and were compared by use of the Student t test or the Mann-Whitney rank-sum test as appropriate. All outcomes were expressed with Kaplan-Meier methodology and compared by use of the log-rank test. The correlation between WBCc and baseline CPK levels was determined by the Pearson correlation coefficient. Analysis was stratified according to patients with a WBCc Ͼ11 000 and Յ11 000 per 1 mm 3 as a cutoff for normal, according to previous studies. 11 Receiver-operating characteristic curves were also constructed to assess the accuracy of WBCc to predict 1-year all-cause mortality, cardiac mortality, noncardiac mortality, and bleeding and of baseline CPK for 1-year cardiac mortality. The optimal cutoff values from the receiver-operating characteristic curves were chosen by use of the Youden index. To assess the association between WBCc and 1-year all cause mortality, cardiac mortality, noncardiac mortality, and major bleeding, Cox multivariable regression analyses were performed. To adjust for possible confounders, a propensity score for high (Ͼ11 000 per 1 mm 3 ) versus low (Յ11 000 per 1 mm 3 ) WBCc was determined by use of a logistic regression model. The following variables were considered for the propensity score: age; sex; diabetes mellitus; smoking; family history of coronary artery disease; hypertension; hypercholesterolemia; baseline CPK; hemoglobin levels and platelet count; prior MI; prior PCI; prior coronary bypass graft surgery; renal dysfunction; Killip class; peripheral vascular disease; anterior myocardial infarction; baseline Thrombolysis in Myocardial Infarction flow; ␤-blocker, angiotensin-converting enzyme inhibitor, oral hypoglycemic, and aspirin therapy at hospital admission; and procedural antithrombotic treatment. The propensity score was then entered into the multivariable analyses as a linear term in 3 separate multivariable Cox models, with WBCc entered as continuous data, by using the cutoff value of 11 000 per 1 mm 3 , or stratified by quartiles. Nonlinearity was checked with Martingale residuals. Because left ventricular ejection fraction (LVEF) at hospital admission was not available in 472 patients (and therefore was excluded in determining the propensity score), multivariable analyses of 1-year mortality and cardiac mortality were also performed in the subset of patients who had LVEF determined. To avoid overfitting, the following variables known to affect prognosis after STEMI were considered in this model: baseline hemoglobin and CPK level measured at hospital admission (the latter to adjust for the degree of myonecrosis at baseline), age, renal dysfunction, Killip class, baseline Thrombolysis in Myocardial Infarction flow, LVEF, and WBCc (as continuous data). Moreover, a propensity score including the 23 variables specified above and LVEF was also determined in this subgroup of patients and entered into the multivariable analysis as a linear term in addition to WBCc as continuous data. The impact of WBCc on outcomes was also assessed after matching patients for baseline CPK levels. Independent predictors of final infarct size, estimated by the peak CPK level, 12 were then examined by use of a multivariable linear regression analysis in the population matched for baseline CPK levels. The following variables were entered into the model: WBCc (as continuous data), baseline hemoglobin and CPK levels measured at hospital admission, age, sex, renal dysfunction, baseline Thrombolysis in Myocardial Infarction grade 0/1 flow, and anterior MI. This model was tested in patients with and in those without measured LVEF. Statistical analyses were performed with SAS version 9.1. Values of PϽ0.05 were considered statistically significant.
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Results
Baseline Characteristics According to White Blood Cell Count
Among the 3602 patients enrolled in the trial, 3345 (92.9%) underwent primary PCI, 3193 of whom (95.5%) had a baseline WBCc available, signifying the present study cohort. As shown in Figure 1 , WBCc was normally distributed. Clinical characteristics of patients stratified by baseline WBCc availability are shown in Table I in the online-only Data Supplement. In general, these 2 groups were well matched, except that patients without baseline WBCc were more likely to have a lower LVEF and a history of MI and coronary revascularization. Clinical characteristics of patients stratified by WBCc are shown in Table 1 . Patients with WBCc Ͼ11 000 compared with Յ11 000 per 1 mm 3 were younger, more likely to be smokers, but less likely to be diabetic, to have renal dysfunction, or to have had prior myocardial infarction, PCI, or coronary artery bypass grafting surgery. Moreover, they were less likely to be on aspirin, ␤-blocker, and angiotensin-converting enzyme inhibitor therapy on hospital admission, although medication use at discharge was not significantly different between the groups. Anatomic and procedural variables stratified by WBCc are shown in Table 2 . Patients with WBCc Ͼ11 000 per 1 mm 3 were slightly more likely to present with preprocedural Thrombolysis in Myocardial Infarction grade 0 flow, were less likely to have a saphenous vein graft as a culprit vessel, and more frequently received bivalirudin. Other baseline variables were independent of WBCc.
Thirty-Day and 1-Year Clinical Outcomes
Follow-up rates in patients with WBCc Յ11 000 versus Ͼ11 000 per 1 mm 3 were 99.4% and 99.7%, respectively, at 30 days (Pϭ0.18) and 97.8% versus 98.3% at 1 year (Pϭ0.37). The median follow-up durations in patients with WBCc Յ11 000 versus Ͼ11 000 per 1 mm 3 were 742 days (interquartile range, 730 to 1094 days) versus 744 days (interquartile range, 731 to 1093 days), respectively (Pϭ0.92). Clinical outcomes were comparable in patients with versus without baseline WBCc available (Table II in the online-only Data Supplement).
As shown in Table 3 , all-cause mortality during the first 30 days was higher in patients with an elevated baseline WBCc (Ͼ11 000 per 1 mm
3 ) compared with a lower WBCc, driven by significantly higher cardiac mortality. The rates of reinfarction, target vessel revascularization, stent thrombosis, stroke, and bleeding did not vary significantly according to WBCc at 30 days. At the 1-year follow-up (Table 3) , all-cause mortality remained higher in patients with an elevated baseline WBCc (Figure 2A ), owing to both higher cardiac ( Figure 2B ) and noncardiac ( Figure 2C ) mortality. Again, no significant differences were apparent in terms of reinfarction, target vessel revascularization, stent thrombosis, stroke, or bleeding, according to WBCc. When stratified by WBCc quartiles, the higher rates of mortality ( Figure 3A) , cardiac mortality ( Figure 3B ), and noncardiac mortality ( Figure 3C ) were confined to patients with the highest quartile of WBCc compared with the other quartiles.
After adjustment for propensity score, WBCc as a continuous variable was an independent predictor of 1-year allcause mortality (hazard ratio [HR] 
Clinical Outcomes in Patients Matched or Stratified for Baseline Creatinine Phosphokinase Levels
A weak correlation was present between baseline WBCc and CPK levels (ϭ0.129; PϽ0.0001). Clinical characteristics of the 2 groups of patients matched for baseline CPK levels are shown in Table IV in the online-only Data Supplement. Of note, the culprit artery, total ischemic time, and door-toballoon time were similar between the 2 groups, except for a slightly higher prevalence of saphenous vein grafts and left main as culprit arteries in the low-WBCc group. The incidence of 1-year mortality was 3.0% in patients with low WBCc (Յ11 000 per 1 WBCc indicates white blood cell count; CAD, coronary artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; CPK, creatinine phosphokinase; ACE, angiotensin-converting enzyme; and ARB, angiotensin receptor blockers. Continuous data are presented as median (interquartile range).
*Total ischemic time is the time from symptom onset to balloon dilatation in minutes. †Arrival from first outside hospital or study hospital to first balloon inflation.
PϽ0
.0001) and in those without measured LVEF (coefficient, 100; 95% CI, 80 to 119; PϽ0.0001). Other independent correlates of peak CPK are shown in Table 4 .
In the receiver-operating characteristic analysis, baseline CPK level was strongly related to 1-year cardiac mortality (area under the curve, 0.64; 95% CI, 0.59 to 0.69; Pϭ0.0002); the value of baseline CPK with the best sensitivity and specificity was 195 U/L. With this cutoff value, patients were grouped into those with low baseline CPK (Յ195 U/L) and those with high baseline CPK (Ͼ195 U/L). As shown in Figure 4 , high WBCc remained an independent predictor of 1-year cardiac mortality in patients with high baseline CPK levels (adjusted HR, 1.14; 95% CI, 1.07 to 1.22; PϽ0.0001). In patients with low baseline CPK, age was the only independent predictor of 1-year cardiac mortality (adjusted HR, 1.05; 95% CI, 1.02 to 1.09; Pϭ0.0008). In patients with low CPK, WBCc (adjusted HR, 1.1; 95% CI, 1.03 to 1.18; Pϭ0.006), age (HR, 1.07; 95% CI, 1.04 to 1.10; PϽ0.0001), and renal insufficiency (HR, 3.57; 95% CI, 1.46 to 8.76; Pϭ0.005) were the only independent predictors of 1-year all-cause death. The risk of 1-year cardiac mortality in patients with high baseline CPK and low WBCc was similar to that of patients with low baseline CPK and a high WBCc. WBCc indicates white blood cell count; LAD, left anterior descending artery; Cx, circumflex artery; RCA, right coronary artery; RIMA, right mammary artery; SVG, saphenous vein graft; TIMI, Thrombolysis in Myocardial Infarction; and POBA, plain balloon angioplasty.
Discussion
The principal findings of our study are the following: (1) The baseline WBCc drawn at the time of presentation with STEMI was an independent predictor of infarct size as assessed by peak CPK level, as well as the 1-year rates of all-cause mortality, cardiac mortality, noncardiac mortality, and major bleeding after primary PCI; and (2) the correlation between WBCc and subsequent mortality was independent of baseline CPK and LVEF.
Prior studies have reported discrepant results regarding the association between WBCc and mortality in patients with STEMI undergoing primary PCI, 4 -7 possibly because of their heterogeneity in terms of sample size, patient selection criteria, cutoff values for WBCc, and statistical methodologies. The present analysis represents the largest study to date addressing the relation between WBCc and mortality, cardiac mortality, noncardiac mortality, and major bleeding in patients after primary PCI and strongly supports significant prognostic utility for this measure. A novel finding from our study is that the association between WBCc and cardiac mortality was independent of baseline CPK levels, an indicator of the extent of myonecrosis at hospital admission (before reperfusion therapy). 13, 14 The correlation between WBCc and baseline CPK was poor, and after correction for measured confounders (including baseline CPK), WBCc remained an independent predictor of 1-year cardiac mortality. Even after patients were stratified for baseline CPK levels, those with high CPK and high WBCc had a significantly higher mortality than those with high CPK and low WBCc. Patients with a high baseline CPK and low WBCc had a rate of 1-year cardiac mortality similar to that of patients with low baseline CPK and high WBCc. The relationship between the baseline WBCc and subsequent cardiac mortality was also independent of baseline LVEF, an important prognostic determinant in patients with STEMI undergoing primary PCI. 15 These data collectively suggest that a high level of systemic inflammation in the early phase of STEMI (as reflected by the WBCc) is strongly associated with 1-year cardiac mortality.
Whether an elevated WBCc is directly responsible for the poor prognosis of patients with STEMI after primary PCI is unknown. Leukocytes may have a prothrombotic effect by producing tissue factor, 16, 17 by providing a catalytic surface for thrombin generation, 18 and/or by forming plateletleukocyte aggregates. 19 An elevated WBCc may also result in diminished microcirculatory perfusion by adhesion, aggregation, platelet recruitment, 20 and release of proinflammatory and vasculotoxic factors. 21 These effects may contribute to reperfusion injury 22 and subsequent extension of myocardial necrosis. The present study is consistent with this mechanism in that a high WBCc was an independent determinant of peak CPK, a direct indicator of final infarct size. 12 Moreover, leukocyte-depleting filters may attenuate myocardial injury during elective coronary artery bypass surgery, 23 and several experimental studies have suggested a beneficial effect of antiinflammatory therapies in reducing reperfusion injury, 24 although clinical evidence remains to be demonstrated. However, causality cannot be proven from the present study, and it is unknown whether an elevated baseline WBCc is simply a marker for unmeasured confounders also correlated with subsequent mortality in STEMI. In this regard, a novel finding of the present study is the observation that a high WBCc was an independent predictor of 1-year noncardiac mortality. To the best of our knowledge, this has not previously been reported. The mechanisms underlying this association are unclear and require further study.
Another noteworthy finding from the present study was the independent association between WBCc and major bleeding. Ndrepepa et al 4 have recently reported an association between high WBCc and bleeding in patients presenting with acute coronary syndromes. We have previously reported this association in patients with unstable angina and non-STEMI from the large-scale Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. 25 A high WBCc has also been reported to be an independent predictor of increased perioperative bleeding in patients undergoing cardiac surgery with cardiopulmonary bypass. 26 Thus, the relationship between an increased WBCc and bleeding in numerous clinical settings has now been established. However, the mechanisms linking high WBCc with major bleeding are unknown and warrant further study.
This report has several limitations that should be acknowledged. As a retrospective analysis from a prospective, randomized trial, the results from this study should be considered hypothesis generating. Information on the WBCc differential count was not available 27 ; however, a prior study has suggested that total WBCc is a better correlate of long-term prognosis than the white blood cell components. 28 WBCc was determined at only 1 time point and therefore may have been subject to regression dilution bias. The receiver-operating characteristic-determined cutoff values in the present study were determined post hoc. The clinical utility of these cutoff values thus requires validation in future studies. We do not have detailed data on C-reactive protein and therefore were unable to explore the relationship between C-reactive protein and WBCc. However, a recent study in patients with acute coronary syndromes undergoing PCI reported that WBCc and not C-reactive protein was an independent predictor of 1-year mortality. 4 Baseline data on corticosteroid and statin usage, which may affect WBCc, were not collected. Finally, the present study demonstrates a strong association between an elevated baseline WBCc, final infarct size, and subsequent mortality, but it does not prove causality. This issue might be addressed in future studies investigating the effect of therapies that decrease WBCc on final infarct size and clinical outcomes. Coller 29 reviewed the potential risks and benefits of WBCc-lowering drugs in this context. 
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